Cellectar Biosciences, Inc.
CLRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001279704
No open-market purchases or sales by Cellectar Biosciences, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $9.08M in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Cellectar Biosciences, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- 0 vs. Q1 2023
- Shares held
- 1.60M
- −114.9K (−6.7%) vs. Q1 2023
- Total value
- $3.08M
- +$645.4K (+26.5%) vs. Q1 2023
- New holders
- 2
- 4 more added
- Sold out
- 2
- 5 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CLRB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 29 | $9.08M |
| Q1 2026 | 19 | $812.9K |
| Q4 2025 | 20 | $1.04M |
| Q3 2025 | 21 | $1.65M |
| Q2 2025 | 19 | $734.0K |
| Q1 2025 | 32 | $1.63M |
| Q4 2024 | 30 | $1.52M |
| Q3 2024 | 35 | $30.0M |
| Q2 2024 | 37 | $28.3M |
| Q1 2024 | 45 | $36.3M |
| Q4 2023 | 26 | $23.9M |
| Q3 2023 | 20 | $3.85M |
| Q2 2023 | 21 | $3.08M |
| Q1 2023 | 21 | $2.43M |
| Q4 2022 | 26 | $3.22M |
| Q3 2022 | 22 | $2.14M |
| Q2 2022 | 33 | $3.61M |
| Q1 2022 | 32 | $4.69M |
| Q4 2021 | 42 | $4.38M |
| Q3 2021 | 40 | $6.77M |
| Q2 2021 | 46 | $14.9M |
| Q1 2021 | 45 | $24.2M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Cellectar Biosciences, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Altshuler Shaham Ltd | 20,000 | $0 | 0.00% | 00.0% | Unchanged |
| Benjamin Edwards Inc | 1 | $0 | 0.00% | 00.0% | Unchanged |
| AllSquare Wealth Management LLC | 18 | $27 | 0.00% | 00.0% | Unchanged |
| Harbour Investments, Inc. | 40 | $78 | 0.00% | 00.0% | Unchanged |
| FMR LLC | 49 | $96 | 0.00% | +49 | New |
| Wells Fargo & Company | 60 | $117 | 0.00% | +4+7.1% | Added |
| US Bancorp | 285 | $556 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 521 | $1.01K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 1,200 | $2.34K | 0.00% | −910−43.1% | Reduced |
| Tower Research Capital LLC (TRC) | 4,843 | $9.44K | 0.00% | +284+6.2% | Added |
| Morgan Stanley | 15,000 | $29.3K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 15,714 | $30.6K | 0.00% | 00.0% | Unchanged |
| Monticello Wealth Management, LLC | 18,000 | $35.1K | 0.00% | +6,000+50.0% | Added |
| Maven Securities LTD | 25,000 | $48.8K | 0.01% | 00.0% | Unchanged |
| Citadel Advisors LLC | 30,790 | $60.0K | 0.00% | +30,790 | New |
| Geode Capital Management, LLC | 46,869 | $91.4K | 0.00% | −374−0.8% | Reduced |
| BlackRock Inc. | 57,042 | $111.2K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 63,990 | $125.0K | 0.00% | +6,589+11.5% | Added |
| Vanguard Group Inc | 171,973 | $335.3K | 0.00% | −3,510−2.0% | Reduced |
| Worth Venture Partners, LLC | 313,509 | $611.3K | 0.33% | −23,091−6.9% | Reduced |
| AIGH Capital Management LLC | 813,197 | $1.59M | 0.65% | −118,691−12.7% | Reduced |
| Bank of New York Mellon Corp | 0 | $0 | 0.00% | −12,037−100.0% | Sold out |
| Mendota Financial Group, LLC | 0 | $0 | 0.00% | −5−100.0% | Sold out |